Through our research programs, we are addressing the barriers that are preventing safer treatments from reaching children. We drive results that will help children in a clinical trial now, not 10-20 years in the future. We support researchers to the point at which an Investigational New Drug (IND) application can be filed and clinical trials opened for pediatric patients. We support international research because the next game-changing therapeutic development could be made outside of the United States and international collaborative projects can pull together the greatest minds for the development of the most effective cures. And, we catapult research into a clinical trial and potential commercialization, the point at which treatments become broadly available to patients.
Through our Catapult Awards, we fund game-changing clinical trials – projects with established commercial potential that will impact patients in the clinic today and potentially provide a new, better standard of care for children everywhere. These critical awards push forward high-potential research into clinical trials and ultimately drug development. Catapult Awards will provide funding support up to $2.5 million for a two- to three-year award period for ‘clinic-ready’ projects.
Catapult Awards – Active PROJECTS
We continue to invest in large-scale awards to ensure sustainable research moves forward at an accelerated pace. We won’t stop until a greater quantity of effective and less-toxic children’s cancer treatments have moved out of the lab and into the clinic, ensuring more children live long, healthy and productive lives.
For more information on Catapult Awards, developing resources or future RFAs, contact:
National Director, Research and Programs
Interested in applying for a CureSearch Research Grant? Click here to be added to our mailing list to be the first to know about new RFAs.